OTCM
OCTHF
Market cap3mUSD
May 08, Last price
0.00USD
Name
Oxford Cannabinoid Technologies Holdings PLC
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-6m
CFO
-7m
Profile
Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate is OCT461201, a selective CB2 receptor agonist in solid oral dosage form that is in pre-clinical development for use in the treatment of IBS-associated visceral pain, as well as neuropathic pain conditions, including post herpetic neuralgia. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY |
|---|---|
| 2023‑04 | |
| Income | |
Revenues | |
Cost of revenue | 6,974 |
Unusual Expense (Income) | |
NOPBT | (6,974) |
NOPBT Margin | |
Operating Taxes | (1,089) |
Tax Rate | |
NOPAT | (5,885) |
Net income | (5,945) |
Dividends | |
Dividend yield | |
Proceeds from repurchase of equity | |
BB yield | |
| Debt | |
Debt current | |
Long-term debt | |
Deferred revenue | |
Other long-term liabilities | |
Net debt | (2,297) |
| Cash flow | |
Cash from operating activities | (6,868) |
CAPEX | |
Cash from investing activities | |
Cash from financing activities | |
FCF | |
| Balance | |
Cash | 2,297 |
Long term investments | |
Excess cash | 2,297 |
Stockholders' equity | (10,123) |
Invested Capital | 14,034 |
ROIC | |
ROCE | |
| EV | |
Common stock shares outstanding | 960,415 |
Price | |
Market cap | |
EV | |
EBITDA | (6,935) |
EV/EBITDA | |
Interest | |
Interest/NOPBT | |